Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Adjuvant Therapy in SNF4 HR+/HER2- Early Breast Cancer
NCT05889871Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of Rivoceranib in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Invasive Disease-Free Survival at 3 years. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05889871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05889871.